Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40265-015-0523-6 http://scihub22266oqcxt.onion/10.1007/s40265-015-0523-6 C4939080!4939080!26729185     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drugs 2016 ; 76 (3): 291-300 Nephropedia Template TP {{tp|p=26729185|t=2016. Targeted therapy for idiopathic pulmonary fibrosis: where to now?|pdf=|usr=}}{{26729185}} gab.com Text Targeted therapy for idiopathic pulmonary fibrosis: where to now JO: Drugs http://www.kidney.de/pget.php?&tw=1&pmid=26729185 #FOAvip Idiopathic pulmonary fibrosis (IPF) is an aging-associated recalcitrant lung disease with historically limited therapeutic options. The recent approval of two drugs, pirfenidone and nintedanib, by the United States Food and Drug Administration (FDA) in 2014 has heralded a new era in its management. Both drugs demonstrated efficacy in Phase III clinical trials by retarding the rate of progression of IPF; neither drug appears to be able to completely arrest disease progression. Advances in the understanding of IPF pathobiology have led to an unprecedented expansion in the number of potential therapeutic targets. Drugs targeting several of these are under investigation in various stages of clinical development. Here, we provide a brief overview of the drugs currently approved, and others in Phase II clinical trials. Future therapeutic opportunities that target novel pathways, including some that are associated with the biology of aging, are examined. A multi-targeted approach, potentially with combination therapies, and the identification of individual (or subsets of) patients who may respond more favorably to specific agents are likely to be more effective. Twit Text FOAVip Targeted therapy for idiopathic pulmonary fibrosis: where to now ????Drugs http://www.kidney.de/pget.php?&tw=1&pmid=26729185 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26729185 #FOAvip English Wikipedia <ref>{{Cite pmid|26729185}}</ref> Targeted therapy for idiopathic pulmonary fibrosis: where to now? #MMPMID26729185 Rangarajan S; Locy ML; Luckhardt TR; Thannickal VJ Drugs 2016[Mar]; 76 (3): 291-300 PMID26729185show ga Idiopathic pulmonary fibrosis (IPF) is an aging-associated recalcitrant lung disease with historically limited therapeutic options. The recent approval of two drugs, pirfenidone and nintedanib, by the United States Food and Drug Administration (FDA) in 2014 has heralded a new era in its management. Both drugs demonstrated efficacy in Phase III clinical trials by retarding the rate of progression of IPF; neither drug appears to be able to completely arrest disease progression. Advances in the understanding of IPF pathobiology have led to an unprecedented expansion in the number of potential therapeutic targets. Drugs targeting several of these are under investigation in various stages of clinical development. Here, we provide a brief overview of the drugs currently approved, and others in Phase II clinical trials. Future therapeutic opportunities that target novel pathways, including some that are associated with the biology of aging, are examined. A multi-targeted approach, potentially with combination therapies, and the identification of individual (or subsets of) patients who may respond more favorably to specific agents are likely to be more effective. äTargeted therapy for idiopathic pulmonary fibrosis: where to now?(epmc).pdf DeepDyve Pubget Overpricing